Purple Biotech Ltd.

Regulatory Filings • May 29, 2022

6K:Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile false

���� ����� ��"�	2 380
PURPLE BIOTECH LTD
Corporation no: 520031238	12724
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	29/05/2022
	www.isa.gov.il			www.tase.co.il				Reference:	2022-02-066196	Time of broadcast: 15:04 15:04

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on6K:Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile

ea160725-6k_purplebiotechEDGAR2_Bannerless_isa.pdf

6K: ����� ����� ����� ������ ���� 1 ������� ������ ������� �� ������ ������� ���� NT219 ���� ASCO 2022
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 27/04/2022
Address: Oppenheimer, Science Park 4 , Rehovot 7670104   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: ir@purple-biotech.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: adim@kitovpharma.com 1
Israel